Colchicine in Patients With Acute Coronary Syndrome The Australian COPS Randomized Clinical Trial
David C Tong, Stephen Quinn, Arthur Nasis, Chin Hiew, Philip Roberts-Thomson, Heath Adams, Rumes Sriamareswaran, Nay M Htun, William Wilson, Dion Stub, William van Gaal, Laurie Howes, Nicholas Collins, Andy Yong, Ravinay Bhindi, Robert Whitbourn, Astin Lee, Chris Hengel, Kaleab Asrress, Melanie Freeman Show all
Circulation | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
BACKGROUND: Inflammation plays a crucial role in clinical manifestations and complications of acute coronary syndromes (ACS). Colchicine, a commonly used treatment for gout, has recently emerged as a novel therapeutic option in cardiovascular medicine owing to its anti-inflammatory properties. We sought to determine the potential usefulness of colchicine treatment in patients with ACS. METHODS: This was a multicenter, randomized, double-blind, placebo-controlled trial involving 17 hospitals in Australia that provide acute cardiac care service. Eligible participants were adults (18-85 years) who presented with ACS and had evidence of coronary artery disease on coronary angiography managed wit..View full abstract
Awarded by National Heart Foundation Future Leader Fellowship
The study was supported by the Cardiology Department of Peninsula Health and St Vincent's Hospital Melbourne, and received philanthropic support from the CASS Foundation (Contributing to Australian Scholarship and Science). Additional funding support was obtained from Peninsula Health and Faculty of Medicine, Nursing and Health Sciences, Monash University. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Dr Stub's research is supported by a National Heart Foundation Future Leader Fellowship (grant 101908). Dr Yong received honoraria from Abbott Vascular and Philips.